文献速递炎症性肠病

新诊断克罗恩病患者早期惰性病程并不罕见且可能可预测

Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-07-03

一项在以色列开展的观察性纵向研究纳入156例新诊断克罗恩病成人患者,中位随访17.2个月,33.3%呈惰性病程。研究基于临床因素建立模型,识别出4个与复杂性病程相关的因素,该模型在诊断后6个月和12个月的判别准确率分别为90%和89%,并在独立验证队列中3个月判别能力为79%。

要点

  • 新诊断克罗恩病患者中约三分之一在早期呈惰性病程。
  • BMI<25 kg/m2、维生素B12<350 pg/mL、白细胞≥7×10^3/μL、ALT≥25 IU/L与复杂性病程相关。
  • 基于上述4因素构建的列线图模型在诊断后6个月和12个月判别准确率分别为90%和89%。

核心结论

  • 在新诊断克罗恩病患者的观察性纵向研究中,约三分之一患者早期呈惰性病程。
  • 研究识别出可在诊断时测量的因素,用于识别早期复杂性病程风险患者,可能用于患者管理和治疗选择。

研究设计与样本

  • 观察性纵向研究,纳入156例新诊断克罗恩病成人患者(79例男性;中位年龄27.7岁;57例未接受过治疗),2013年至2017年从以色列医疗中心和社区诊所转诊而来。
  • 参与者每半年接受一次计划评估;惰性病程定义为无需严格控制复杂病程的干预(住院或手术,或决定开始激素、免疫调节剂或生物制剂治疗)。
  • 采用Cox回归和受试者工作特征分析识别与早期惰性或复杂性病程相关的因素。
  • 在2018年以色列另一医疗中心的独立克罗恩病患者队列中验证发现。

主要发现

  • 中位随访17.2个月(四分位距8.8-23.8个月)期间,52例(33.3%)呈惰性病程,29例(18.5%)需要住院,75例(48%)被建议开始激素、免疫调节剂或生物制剂治疗。
  • 首次干预的中位时间为3.4个月(95%CI,2.4-4.4)。
  • 在未接受过治疗的患者中,与复杂性病程相关的4个因素为:体重指数<25 kg/m2(HR 2.45;95%CI,1.07-5.43;P=.033)、血清维生素B12水平<350 pg/mL(HR 2.78;95%CI,1.21-6.41;P=.016)、白细胞≥7×10^3/μL(HR 2.419;95%CI,1.026-5.703;P=.044)、血清ALT≥25 IU/L(HR 2.680;95%CI,1.186-6.058;P=.018)。
  • 该模型在诊断后6个月和12个月区分有无复杂性病程的准确率分别为90%和89%。
  • 验证队列在诊断后3个月的判别能力为79%,并构建了列线图。

关键数值与推荐

  • 惰性病程定义:无需住院或手术,且未决定开始激素、免疫调节剂或生物制剂治疗的病程。
  • 复杂性病程相关因素:体重指数<25 kg/m2(HR 2.45;95%CI,1.07-5.43;P=.033)。
  • 复杂性病程相关因素:血清维生素B12<350 pg/mL(HR 2.78;95%CI,1.21-6.41;P=.016)。
  • 复杂性病程相关因素:白细胞≥7×10^3/μL(HR 2.419;95%CI,1.026-5.703;P=.044)。
  • 复杂性病程相关因素:血清ALT≥25 IU/L(HR 2.680;95%CI,1.186-6.058;P=.018)。

临床怎么用

  • 作者认为,在诊断时可测量的因素可用于识别早期复杂性病程风险患者,并可能用于患者管理和治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The early stages of Crohn's disease (CD) course are heterogeneous, and it is a challenge to predict the course of disease in patients with new diagnosis. METHODS: We performed an observational longitudinal study of 156 adults (79 male; median age, 27.7 years; 57 treatment naïve) with newly diagnosed CD (within 6 months of enrollment), referred from medical centers and community clinics in Israel from 2013 through 2017. Study participants each received semi-annual scheduled evaluations. Indolent disease was defined as a disease course without need for strict interventions to control complicated course of CD (hospitalization or surgery, or decision to start steroid, immunomodulator, or biologic therapy). Cox regression and receiver operating characteristic analyses were used to identify factors associated with early indolent or complicated course of CD. We validated our findings in an independent cohort of patients with CD from a separate medical center in Israel in 2018. RESULTS: Over a median follow-up period of 17.2 months (interquartile range, 8.8-23.8 months), 52 patients (33.3%) had an indolent course of CD, 29 (18.5%) required hospitalizations, and 75 (48%) were recommended to start steroid, immunomodulator, or biologic therapies. The median time to first intervention was 3.4 months (95% CI, 2.4-4.4). We developed a model based on clinical factors that identified 4 factors associated with complicated course in treatment-naïve patients: body mass index <25 kg/m2 (hazard ratio [HR], 2.45; 95% CI, 1.07-5.43; P = .033), serum level of vitamin B12 <350 pg/mL (HR, 2.78; 95% CI, 1.21-6.41; P = .016), white blood cells ≥7 × 103/μL (HR, 2.419; 95% CI, 1.026-5.703; P = .044), and serum level of ALT ≥25 IU/L (HR, 2.680; 95% CI, 1.186-6.058; P = .018). This model discriminated between patients with vs without a complicated course of disease with 90% and 89% accuracy at 6 and 12 months after diagnosis, respectively. A validation cohort demonstrated a discriminatory ability of 79% at 3 months after diagnosis, and a nomogram was constructed. CONCLUSIONS: In an observational longitudinal study of 156 patients with newly diagnosed CD, we found that one third have an early indolent course of disease. We identified factors that can be measured at diagnosis to identify patients at risk for an early complicated course-these might be used in patient management and selection of treatment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Yanai H, Goren I, Godny L, et al. Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable. Clin Gastroenterol Hepatol. 2020. PMID: 32629126. doi:10.1016/j.cgh.2020.06.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。